CorVel Corp. (NASDAQ:CRVL – Get Free Report) Director Jeffrey Michael sold 9,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $60.98, for a total transaction of $548,820.00. Following the transaction, the director owned 559,721 shares of the company’s stock, valued at $34,131,786.58. This represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
CorVel Stock Performance
NASDAQ:CRVL opened at $60.34 on Friday. The company has a fifty day moving average of $57.99 and a two-hundred day moving average of $60.27. The stock has a market capitalization of $3.06 billion, a PE ratio of 28.20 and a beta of 0.99. CorVel Corp. has a fifty-two week low of $44.83 and a fifty-two week high of $106.16.
CorVel (NASDAQ:CRVL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. The company had revenue of $248.55 million during the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%.
Institutional Investors Weigh In On CorVel
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. Weiss Ratings cut shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
View Our Latest Research Report on CorVel
About CorVel
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Featured Articles
- Five stocks we like better than CorVel
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
